Inmune Bio (INMB) Non Operating Income (2020 - 2026)
Inmune Bio (INMB) posted Non Operating Income of $405000.0 for Q1 2026, up 92.86% sequentially from $210000.0 in Q4 2025, and up 143.98% YoY from $166000.0 in Q1 2025.
Inmune Bio (INMB) Non Operating Income (2020 - 2026) Analysis & Trends
Inmune Bio has reported Non Operating Income for 7 years, with the latest figure at $405000.0 in Q1 2026.
- Quarterly Non Operating Income rose 143.98% year-over-year to $405000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 132.32% YoY) and the FY2025 annual result came in at $1.4 million, up 162.21% from the prior year.
- Non Operating Income rose to $405000.0 in Q1 2026 per INMB's latest filing, from $210000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $961000.0 in Q3 2025 and troughed at -$425000.0 in Q1 2022.
- A 5-year average of $175181.8 and a median of $166000.0 in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 5212.5% in 2022, then soared 958.62% in 2024.
- Over 5 years, Non Operating Income stood at -$425000.0 in 2022, then jumped by 93.18% to -$29000.0 in 2023, then jumped by 958.62% to $249000.0 in 2024, then retreated by 15.66% to $210000.0 in 2025, then surged by 92.86% to $405000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $405000.0, $210000.0, and $961000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 203,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 203,000.00 |
| Mar 31, 2026 | 405,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Sep 30, 2025 | 961,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 249,000.00 |
| Sep 30, 2024 | 193,000.00 |
| Jun 30, 2024 | 119,000.00 |
| Dec 31, 2023 | -29,000.00 |
| Sep 30, 2023 | -35,000.00 |
| Mar 31, 2022 | -425,000.00 |
| Dec 31, 2021 | -641,000.00 |
| Sep 30, 2021 | -437,000.00 |
| Jun 30, 2021 | -101,000.00 |
| Mar 31, 2021 | -8,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 103,000.00 |
| Jun 30, 2020 | -1,000.00 |
| Mar 31, 2020 | 22,000.00 |